BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 2nd Quarter - Report

NIELSEN BIOSCIENCES, INC.

via PRIME POLICY GROUP

2nd Quarter (Apr 1 - June 30) · 2013Posted Jul 22, 2013Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: NIELSEN BIOSCIENCES, INC.
Description: Orphan drug development
Location: California · United States of America

Registrant

Firm: PRIME POLICY GROUP
Description: Government relations
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medical/Disease Research/Clinical Labs
FDA user fee issue.
LobbyistsVICKIE WALLING
TargetedHOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

NIELSEN BIOSCIENCES, INC. — Lobbying — Receipts Report